Pip2 as a marker for hdl function and cardiovascular disease risk

A method performing an activity based on concentration level of PIP2 phospholipid in a biological sample from a subject comprising:

• a) determining the concentration level of total PIP2 in a biological sample from a subject, and/or determining the concentration level of HDL-associated PIP2 in said biological sample from said subject;
• and
• b) performing at least one of the following:
• i) identifying decreased total or HDL-associated PIP2 levels in said biological sample, and treating said subject with a CVD therapeutic agent;
• ii) generating and/or transmitting a report that indicates said total or HDL-associated PIP2 levels are decreased in said sample, and that said subject is in need of a CVD therapeutic agent;
• iii) generating and/or transmitting a report that indicates said total or HDL-associated PIP2 levels are decreased in said sample, and that said subject has or is at risk of cardiovascular disease or complication of cardiovascular disease;
• iv) generating and/or transmitting a report that indicates said total or HDL-associated PIP2 levels are elevated in said sample, and that said subject has increased reverse-cholesterol transport function;
• v) characterizing said subject as having CVD or having an increased risk for having or developing CVD.